Surgical Treatment of Uterine Leiomyomas from 2016-2022 in the Republic of Kazakhstan

ORIGINAL ARTICLE
Z. E. Barmanasheva, D. V. Dzhakupov, T. K. Kudaibergenov, M. V. Laktionova

 
For citation: Barmanasheva ZE, Dzhakupov DV, Kudaibergenov TK, Laktionova MV. Surgical Treatment of Uterine Leiomyomas from 2016-2022 in the Republic of Kazakhstan. International Journal of Biomedicine. 2024;14(1):118-121. doi:10.21103/ Article14(1)_OA18
 
Originally published March 1, 2024

Abstract: 

Background: Due to the transition to a mandatory health insurance system (MHIS) and also taking into account the impact of the COVID-19 pandemic, the purpose of this study was to evaluate the surgical treatment of uterine leiomyoma in Kazakhstan in recent years, taking into account the ratio of uterine-preserving surgery (UPS) and hysterectomy.
Methods and Results: This epidemiological study was carried out upon the request of the Republican E-Health Center (RCEZ) to assess the dynamics of surgical treatment of uterine leiomyomas (UL) in Almaty at the expense of the Republican budget from 2016 to 2022. Since 2016, by 2022 there was a decrease in the total number of treated cases of UL at the expense of the Republican budget (from 1,478 to 1,063). From 2016 to 2019, there were statistically significantly more hysterectomies, whereas from 2020 to 2022 the number of uterine-preserving surgeries increased statistically significantly. The number of laparoscopic myomectomy and hysteroscopic myomectomy for treating submucous leiomyomas increased statistically significantly from 2016 to 2019. However, there were no statistical differences in the number of treated cases with this technique from 2020 to 2022.
Conclusion: Although high-tech fibroid surgery has been performed more frequently in recent years, these numbers are insufficient today, which justifies the need to train more specialists in advanced technologies.

Keywords: 
uterine leiomyomas • myomectomy • uterine-preserving surgery
References: 
  1. Sanders AP, Chan WV, Tang J, Murji A. Surgical outcomes after uterine artery occlusion at the time of myomectomy: systematic review and meta-analysis. Fertil Steril. 2019 Apr;111(4):816-827.e4. doi: 10.1016/j.fertnstert.2018.12.011. Epub 2019 Jan 17. PMID: 30661604.
  2. Hiratsuka D, Isono W, Tsuchiya A, Okamura A, Fujimoto A, Nishii O. The effect of temporary uterine artery ligation on laparoscopic myomectomy to reduce intraoperative blood loss: A retrospective case-control study. Eur J Obstet Gynecol Reprod Biol X. 2022 Aug 8;15:100162. doi: 10.1016/j.eurox.2022.100162. PMID: 36035234; PMCID: PMC9399157.
  3. Bulun SE. Uterine fibroids. N Engl J Med. 2013 Oct 3;369(14):1344-55. doi: 10.1056/NEJMra1209993. PMID: 24088094.
  4. Styer AK, Rueda BR. The Epidemiology and Genetics of Uterine Leiomyoma. Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:3-12. doi: 10.1016/j.bpobgyn.2015.11.018. Epub 2015 Dec 2. PMID: 26725703.
  5. Tranoulis A, Georgiou D, Alazzam M, Borley J. Combined Laparoscopic Uterine Artery Occlusion and Myomectomy versus Laparoscopic Myomectomy: A Direct-Comparison Meta-Analysis of Short- and Long-Term Outcomes in Women with Symptomatic Leiomyomas. J Minim Invasive Gynecol. 2019 Jul-Aug;26(5):826-837. doi: 10.1016/j.jmig.2019.02.004. Epub 2019 Feb 15. PMID: 30776497.
  6. Tixier H, Grevoul J, Loffroy R, Lauferon J, Guiu B, Mutamba W, Filipuzzi L, Cercueil JP, Douvier S, Krause D, Sagot P. Preoperative embolization or ligature of the uterine arteries in preparation for conservative uterine fibroma surgery. Acta Obstet Gynecol Scand. 2010 Oct;89(10):1310-5. doi: 10.3109/00016349.2010.512060. PMID: 20726700.
  7. Yang W, Cheng Z, Yu J, Yang H, Liu Z, Ren Q, Xu L. Multicentre study to evaluate the clinical effects of laparoscopic uterine artery occlusion in combination with myomectomy to treat symptomatic uterine leiomyomas. Eur J Obstet Gynecol Reprod Biol. 2016 Sep;204:9-15. doi: 10.1016/j.ejogrb.2016.05.033. Epub 2016 May 26. PMID: 27471836.

Download Article
Received January 15, 2024.
Accepted February 20, 2024.
©2024 International Medical Research and Development Corporation.